CHPA Statement on FDA Releasing Briefing Materials for OPILL Joint Advisory Committee Meeting

Share page:

(WASHINGTON, D.C.) – The Consumer Healthcare Products Association (CHPA) today released the below statement following the U.S. Food and Drug Administration’s (FDA) public release of briefing materials for next week’s joint meeting of the Nonprescription Drugs Advisory Committee and the Obstetrics, Reproductive and Urologic Drugs Advisory Committee to discuss the supplemental new drug application (sNDA) for OPILL, a daily oral contraceptive:

“CHPA is pleased to see the Rx-to-OTC switch pathway being used once again to evaluate broadened access to beneficial consumer healthcare products,” said David Spangler, CHPA’s SVP of Legal, Government Affairs & Policy. “Should the sponsor’s application ultimately be approved, this switch would be a win-win for both consumers and the entire U.S. healthcare system. Not only does increased access to OTC medicines benefit individuals by empowering them to take greater control over their own health, but OTC access also helps save our healthcare system billions of dollars annually. CHPA looks forward to sharing industry perspectives next week in support of the specific public health and consumer benefits associated with better access to contraceptives.”  

The Consumer Healthcare Products Association (CHPA), founded in 1881, is the national trade association representing the leading manufacturers and marketers of consumer healthcare products, including over-the-counter (OTC) medicines, dietary supplements, and consumer medical devices. CHPA is committed to empowering self-care by ensuring that Americans have access to products they can count on to be reliable, affordable, and convenient, while also delivering new and better ways to get and stay healthy. Visit